VEGFA and uveal melanoma: Moreover, a clinical study in uveal melanoma patients indicated that ANGPTL4 secretion is controlled by hypoxia-inducible factor-1 (HIF-1) and interactions with VEGF to enhance angiogenesis, implying the potential benefit of combined inhibition of ANGPTL4 and VEGF to improve the efficacy of antiangiogenic therapy [42].